Chronic Obstructive Pulmonary Disease

BASICS

DESCRIPTION
Chronic obstructive pulmonary disease encompasses several diffuse pulmonary diseases including chronic bronchitis, asthma, cystic fibrosis, bronchiectasis, and emphysema. The term usually refers to a mixture of chronic bronchitis and emphysema.
  • Chronic bronchitis is defined clinically by increased mucus production and recurrent cough present on most days for at least three months during at least two consecutive years.
  • Emphysema is the destruction of interalveolar septa. The disease occurs in the distal or terminal airways and involves both airways and lung parenchyma.
  • System(s) affected: Pulmonary
  • Genetics:
    • Chronic bronchitis is not a genetic disorder although some studies have hinted at a predisposition for development of this condition.
    • A rare form of emphysema, antiprotease deficiency (due to alpha 1-antitrypsin deficiency), is an inherited disorder that is an expression of two autosomal codominant alleles.
  • Incidence/Prevalence in USA:
    • 10-20% of adults; more than 60,000 deaths/year
    • 8 million people have chronic bronchitis; 2 million people have emphysema
  • Predominant age: Over 40 years
  • Predominant sex: Male > Female
SIGNS AND SYMPTOMS
  • Chronic bronchitis
    • Cough
    • Sputum production
    • Frequent infections
    • Intermittent dyspnea
    • Pedal edema
    • Plethora
    • Cyanosis
    • Wheezing
    • Weight gain
    • Diminished breath sounds
  • Emphysema
    • Minimal cough
    • Scant sputum
    • Dyspnea
    • Often significant weight loss
    • Occasional infections
    • Barrel chest
    • Minimal wheezing
    • Use of accessory muscles of respiration
    • Pursed lip breathing
    • Cyanosis is slight or absent
    • Chronic obstructive pulmonary disease & emphysema
CAUSES
  • Cigarette smoking
  • Air pollution
  • Antiprotease deficiency
  • Occupational exposure (i.e., firefighters)
  • Infection possibly (viral)
RISK FACTORS
  • Passive smoking (especially adults whose parents smoked)
  • Severe viral pneumonia early in life
  • Aging
  • Ethyl alcohol (EtOH) consumption
  • Airway hyperactivity

DIAGNOSIS

LABORATORY
  • Chronic bronchitis
    • Hypercapnia
    • Polycythemia
    • Hypoxia can be moderate to severe
  • Emphysema
    • Normal serum hemoglobin or polycythemia
    • Normal PaCO2; unless FEV1 < 1 L/sec, then can be elevated
    • Mild hypoxia

Drugs that may alter lab results: Sedatives including alcohol
Disorders that may alter lab results: Obesity, concurrent restrictive lung dysfunction, primary pulmonary hypertension, acute infections, anemia, pulmonary embolism sleep apnea, congestive heart failure

PATHOLOGICAL FINDINGS
  • Chronic bronchitis
    • Bronchial mucous gland enlargement
    • Increased number of secretory cells in surface epithelium
    • Thickened small airways from edema and inflammation
    • Smooth muscle hyperplasia
    • Mucus plugging
    • Bacterial colonization of airways
  • Emphysema
    • Entire lung affected
    • Bronchi usually clear of secretions
    • Anthracotic pigment
    • Alveoli enlarged with loss of septa
    • Cartilage atrophy
    • Bullae
SPECIAL TESTS
  • Pulmonary function testing
    • Decreased FEV1 with concomitant reduction in FEV1/FVC ratio
    • Poor or absent reversibility to bronchodilators
    • FVC may be normal or reduced
    • Normal or increased total lung capacity
    • Increased residual volume
    • Diffusing capacity is normal or reduced
  • Nocturnal oximetry
IMAGING
  • Chronic bronchitis chest x-ray shows increased bronchovascular markings and cardiomegaly
  • Emphysema chest x-ray shows small heart, hyperinflation, flat diaphragms and possibly bullous changes
  • CAT scan may show bullous changes
DIAGNOSTIC PROCEDURES
  • Pulmonary function tests
  • ABGs
  • Chest x-ray

TREATMENT

APPROPRIATE HEALTH CARE
  • Outpatient treatment is usually adequate. However, hospitalization may be required for exacerbation, infection, or diagnostic procedures (i.e., transbronchial lung biopsy).
  • Acute respiratory failure may require an intensive care unit and possibly a mechanical ventilator to support the patient
GENERAL MEASURES
  • Smoking cessation
  • Aggressive treatment of infections
  • Treat any reversible bronchospasm
  • Reduction of secretions through good pulmonary hygiene
  • Cor pulmonale may necessitate use of home oxygen
  • Pulmonary rehabilitation
  • Appropriate vaccinations
  • Adequate hydration
SURGICAL MEASURES
  • Lung reduction surgery (selected cases)
  • Lung transplantation (selected cases)
ACTIVITY

As tolerated. Full activity should be encouraged.

DIET

A well balanced, high protein diet is suggested. Low carbohydrates may benefit those with hypercarbia.

PATIENT EDUCATION
  • Printed material is available from the National Jewish Hospital in Denver, Colorado. The local branch of the American Lung Association also has educational material.
  • Coach patients in pulmonary rehabilitation

FOLLOW UP

PREVENTION/AVOIDANCE

Avoidance of smoking is the most important preventive measure. Passive smoke also has been shown to be harmful.

POSSIBLE COMPLICATIONS
  • Infection is common
  • Cor pulmonale, secondary polycythemia, bullous lung disease, acute or chronic respiratory failure, pulmonary hypertension, malnutrition, pneumothorax
EXPECTED COURSE AND PROGNOSIS
  • The patient's age and post-bronchodilator forced expiratory volume (FEV1) are the most important predictors of prognosis. Young age and FEV1 > 50% predicted have a good prognosis. Older patients with more severe lung disease do worse.
  • Supplemental oxygen, when indicated, has been shown to increase survival
  • Smoking cessation is also important for an improved prognosis
  • Malnutrition, cor pulmonale, hypercapnia and pulse > 100 indicate a poor prognosis

MISCELLANEOUS

ASSOCIATED CONDITIONS
  • Lung cancer
  • Coronary artery disease
  • Peptic ulcer disease
  • Chronic sinusitis
  • Malnutrition
  • Laryngeal carcinoma
AGE-RELATED FACTORS

Pediatric: Repeated childhood respiratory illnesses make COPD a greater risk
Geriatric: Relative risk is 1.2 to 2.3 times greater than in younger person
Others: Unusual under age 25 unless antiprotease deficiency is present. Incidence increases as age approaches 60.

PREGNANCY

N/A

OTHER NOTES
  • Albuterol is also known as salbutamol
  • Other important considerations for treatment include adequate hydration, supplemental oxygen, antibiotics when indicated, mucolytic agents, pulmonary rehabilitation, good pulmonary hygiene
ABBREVIATIONS

FVC = forced vital capacity
FEV1 = forced expiratory volume at 1 second
COPD = chronic obstructive pulmonary disease
ABG = arterial blood gases

Clinical Investigations

ROLE OF HOMOEOPATHY

Copyright © 2025 Selkey. All Rights Reserved.